Research Groups

Section of Molecular Pathology

Recent Publications - 12 most recent publications

1. Kim Y.H., Ohta T., Oh J.E., Le Calvez-Kelm F., McKay J., Voegele C., Durand G., Mittelbronn M., Kleihues P., Paulus W., Ohgaki H. (2014) TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors American journal of pathology; 184(9):2374-2381. PMID: 25041856

2. Gheit T., Abedi-Ardekani B., Carreira C., Missad C.G., Tommasino M., Torrente M.C. (2014) Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma J Med.Virol.; 86(4):642-646. PMID: 24374907

3. Ohgaki H., Burger P., Kleihues P. (2014) Definition of primary and secondary glioblastoma--response Clinical cancer research; 20(7):2013. PMID: 24557936

4. Baumgarten P., Harter P.N., Tonjes M., Capper D., Blank A.E., Sahm F., von Deimling A., Kolluru V., Schwamb B., Rabenhorst U., Starzetz T., Kogel D., Rieker R.J., Plate K.H., Ohgaki H., Radlwimmer B., Zornig M., Mittelbronn M. (2014) Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity Neuropathol.Appl.Neurobiol.; 40(2):205-216. PMID: 24117486

5. Fiaschetti G., Abela L., Nonoguchi N., Dubuc A.M., Remke M., Boro A., Grunder E., Siler U., Ohgaki H., Taylor M.D., Baumgartner M., Shalaby T., Grotzer M.A. (2014) Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma Br.J Cancer; 110(3):636-647. PMID: 24346283

6. Nonoguchi N., Ohta T., Oh J.E., Kim Y.H., Kleihues P., Ohgaki H. (2013) TERT promoter mutations in primary and secondary glioblastomas Acta Neuropathol.; 126(6):931-937. PMID: 23955565

7. Sasaki A., Yokoo H., Tanaka Y., Homma T., Nakazato Y., Ohgaki H. (2013) Characterization of microglia/macrophages in gliomas developed in S-100beta-v-erbB transgenic rats Neuropathology.; 33(5):505-514. PMID: 23331472

8. Ohgaki H., Kleihues P. (2013) The definition of primary and secondary glioblastoma Clin Cancer Res.; 19(4):764-772. PMID: 23209033

9. Motomura K., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Sure U., Wrede K., Nakazato Y., Tanaka Y., Nonoguchi N., Pierscianek D., Kim Y.H., Mariani L., Vital A., Perry A., Ohgaki H. (2013) PDGFRA gain in low-grade diffuse gliomas Journal of neuropathology and experimental neurology; 72(1):61-66. PMID: 23242283

10. Pierscianek D., Kim Y.H., Motomura K., Mittelbronn M., Paulus W., Brokinkel B., Keyvani K., Wrede K., Nakazato Y., Tanaka Y., Mariani L., Vital A., Sure U., Ohgaki H. (2013) MET gain in diffuse astrocytomas is associated with poorer outcome Brain pathology; 23(1):13-18. PMID: 22672415

11. Wozniak M.B., Le Calvez-Kelm F., Abedi-Ardekani B., Byrnes G., Durand G., Carreira C., Michelon J., Janout V., Holcatova I., Foretova L., Brisuda A., Lesueur F., McKay J., Brennan P., Scelo G. (2013) Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States PLoS.One.; 8(3):e57886. PMID: 23526956

12. Badiali M., Gleize V., Paris S., Moi L., Elhouadani S., Arcella A., Morace R., Antonelli M., Buttarelli F.R., Figarella-Branger D., Kim Y.H., Ohgaki H., Mokhtari K., Sanson M., Giangaspero F. (2012) KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults Brain pathology; 22(6):841-847. PMID: 22591444